1. Home
  2. PHAR vs LQDT Comparison

PHAR vs LQDT Comparison

Compare PHAR & LQDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • LQDT
  • Stock Information
  • Founded
  • PHAR 1988
  • LQDT 1999
  • Country
  • PHAR Netherlands
  • LQDT United States
  • Employees
  • PHAR N/A
  • LQDT N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • LQDT Catalog/Specialty Distribution
  • Sector
  • PHAR Health Care
  • LQDT Consumer Discretionary
  • Exchange
  • PHAR Nasdaq
  • LQDT Nasdaq
  • Market Cap
  • PHAR 1.0B
  • LQDT 842.1M
  • IPO Year
  • PHAR N/A
  • LQDT 2006
  • Fundamental
  • Price
  • PHAR $14.60
  • LQDT $27.23
  • Analyst Decision
  • PHAR Strong Buy
  • LQDT Strong Buy
  • Analyst Count
  • PHAR 3
  • LQDT 2
  • Target Price
  • PHAR $30.00
  • LQDT $38.50
  • AVG Volume (30 Days)
  • PHAR 11.5K
  • LQDT 221.8K
  • Earning Date
  • PHAR 10-23-2025
  • LQDT 08-07-2025
  • Dividend Yield
  • PHAR N/A
  • LQDT N/A
  • EPS Growth
  • PHAR N/A
  • LQDT 33.77
  • EPS
  • PHAR N/A
  • LQDT 0.83
  • Revenue
  • PHAR $339,836,000.00
  • LQDT $465,508,000.00
  • Revenue This Year
  • PHAR $16.63
  • LQDT $31.57
  • Revenue Next Year
  • PHAR $6.77
  • LQDT $2.58
  • P/E Ratio
  • PHAR N/A
  • LQDT $32.79
  • Revenue Growth
  • PHAR 22.44
  • LQDT 38.40
  • 52 Week Low
  • PHAR $7.06
  • LQDT $21.23
  • 52 Week High
  • PHAR $17.08
  • LQDT $39.72
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 57.37
  • LQDT 60.39
  • Support Level
  • PHAR $13.51
  • LQDT $26.12
  • Resistance Level
  • PHAR $15.61
  • LQDT $27.13
  • Average True Range (ATR)
  • PHAR 0.87
  • LQDT 0.58
  • MACD
  • PHAR -0.06
  • LQDT 0.02
  • Stochastic Oscillator
  • PHAR 59.37
  • LQDT 85.98

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About LQDT Liquidity Services Inc.

Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.

Share on Social Networks: